These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8254733)

  • 1. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.
    el-Farrash MA; Kuroda MJ; Kitazaki T; Masuda T; Kato K; Hatanaka M; Harada S
    J Virol; 1994 Jan; 68(1):233-9. PubMed ID: 8254733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.
    Dis Markers; 1990; 8(3):162-3. PubMed ID: 2125537
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
    Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
    J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.
    Zennou V; Mammano F; Paulous S; Mathez D; Clavel F
    J Virol; 1998 Apr; 72(4):3300-6. PubMed ID: 9525657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
    Bally F; Martinez R; Peters S; Sudre P; Telenti A
    AIDS Res Hum Retroviruses; 2000 Sep; 16(13):1209-13. PubMed ID: 10957718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
    Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
    J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
    Rosé JR; Babé LM; Craik CS
    J Virol; 1995 May; 69(5):2751-8. PubMed ID: 7535864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Maguire MF; Guinea R; Griffin P; Macmanus S; Elston RC; Wolfram J; Richards N; Hanlon MH; Porter DJ; Wrin T; Parkin N; Tisdale M; Furfine E; Petropoulos C; Snowden BW; Kleim JP
    J Virol; 2002 Aug; 76(15):7398-406. PubMed ID: 12097552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.
    Carrillo A; Stewart KD; Sham HL; Norbeck DW; Kohlbrenner WE; Leonard JM; Kempf DJ; Molla A
    J Virol; 1998 Sep; 72(9):7532-41. PubMed ID: 9696850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.
    La Seta Catamancio S; De Pasquale MP; Citterio P; Kurtagic S; Galli M; Rusconi S
    J Clin Microbiol; 2001 Mar; 39(3):1124-9. PubMed ID: 11230439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs.
    Kaufmann GR; Suzuki K; Cunningham P; Mukaide M; Kondo M; Imai M; Zaunders J; Cooper DA
    AIDS Res Hum Retroviruses; 2001 Apr; 17(6):487-97. PubMed ID: 11350662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing.
    Chiu HC; Wang FD; Chen YA; Wang CT
    J Gen Virol; 2006 Jul; 87(Pt 7):2041-2046. PubMed ID: 16760407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
    Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
    Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.